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Objectives: To assess fatty acid (FA) profiles in whole blood of 90 cystic fibrosis patients (CF) and 30 control subjects (C) and to correlate FA
changes to the severity of respiratory disease.
Methods: Whole blood FA were assessed by GC with a micromethod-based analysis.
Results: Saturated and monounsaturated FA are higher, whereas polyunsaturated FA are lower in CF versus C with reduction of total n-6 FA,
22:5n-3 and 22:6n-3 (DHA). The product of linoleic acid (LA) × DHA, proposed as a marker for the disease, is 30% lower in CF than in C.
Correlations with the severity of the respiratory disease are present for different FA and for the LA × DHA product. There is a reduction of Δ5
desaturase activity in CF, greater in severe disease, suggesting a basic metabolic alteration.
Conclusions: The micromethod-based analysis of blood FA facilitates the assessment of the FA status while confirming alterations of FA profiles
already reported in specific blood compartments of CF.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Whole blood fatty acids; Fatty acid desaturation; Pulmonary disease1. Introduction
Cystic fibrosis (CF) is a disease caused by different mutations
in the gene that regulates the synthesis of the transmembrane
conductance regulator (CFTR) leading to CFTR protein dysfunc-
tions. In physiological conditions CFTR, expressed in the apical☆ Part of the data reported in the MS were presented at the 8th ISSFAL
Congress — Kansas City(USA) 2008, May 17–22.
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1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.03.002membrane of epithelial cells, regulates some ion channel
functions, mainly that of chloride [1,2]. The main clinical
symptoms of CF are salt loss through sweat, pancreatic
insufficiency, lipid malabsorption, susceptibility to pulmonary
infections; increased inflammatory responses have also been
found in patients [3,4].
Abnormalities in the fatty acid (FA) turnover and consequently
changes in FA profiles have also been observed, in circulating
lipids [5]. Several studies have shown that the alterations of FA are
not dependent upon pancreatic insufficiency, lipid malabsorption,
occurring in about 80% of CF patients, or secondary to inadequate
energy intake, but can be attributed to the genetic alteration,
although through unknownmechanisms [6]. In particular, levels ofd by Elsevier B.V. All rights reserved.
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(EFA) in our diet, are lower in CF. In plasma phospholipids (PL)
low levels of docosahexaenoic acid (DHA, 22:6 n-3) and
eicosapentaenoic acid (EPA, 20:5 n-3), and increased levels of
monounsaturated FA (MUFA)were also found. No differencewas
reported for arachidonic acid (AA, 20:4 n-6) levels in PL of CF
versus control subjects while in vitro the release of free AA from
cell lipids is increased [7,8].
The increased inflammatory processes characteristic of CF
patients can be partially attributed to an increased production of
eicosanoids derived from the released AA. In this respect, a
recent meta-analysis indicates that the protracted regular
supplementation of n-3 FA has some favourable effects in CF
patients, e.g. reduction of serum immunoglobulin G and α1
antitrypsin, a significant FEV1 (forced respiratory volume in one
second) amelioration, and production of leukotriene (LT) B5
[9,10]. In pancreatic tissues of CFTR knockout mice and in
patients, an increase of the AA/DHA ratio has been reported.
The increase of this ratio found in plasma of CF may be
secondary to reduced DHA levels in face of preserved AA levels
[6,11].
The aim of our study was to confirm: 1. these changes in a
large group of CF children in order to assess whether alterations
in FA metabolism are directly correlated to the severity of the
pulmonary disease, and 2. the usefulness of a facilitated method,
developed in our laboratory, assessing the FA “status” in CF
patients through the FA analysis from a blood drop collected on
a special adsorbent [12]. Whole blood FA profiles, in fact,
correlate with physiological and dietary parameters and are
representative of the FA status in humans, being the expression
of the FA composition of both circulating lipids and cells
[13,14].2. Methods
2.1. Subjects
90 CF patients (41 males and 49 females) attending to the
Cystic Fibrosis Centre of Verona, Italy and to the Cystic
Fibrosis Service at the Spedali Civili of Brescia, Italy and 30
(12 males and 18 females) healthy control children undergoing
routine measurements of biochemical parameters were inves-
tigated. The study was approved by the Ethical Committee of
Azienda Ospedaliera di Verona and informed consent was
obtained from all subjects and from parents of children under
18 years. The diagnosis of CF was based on a positive sweat test
(CL — N60 mEq/L) and the presence of at least one disease
associated mutation in CFTR gene. The 86% of CF presents
pancreatic insufficiency (evaluated by assessing faecal fat of
72 h, faecal chymotrypsin and elastase) and is treated with
pancreatic enzymes, following standard protocols, to prevent
any malabsorption and malnutrition problem. Concerning the
CF genotype the 73% of the patients has the most common
mutation FΔ508 (38% of which are homozygous), the 8% the
R1162X mutation (75% of which are homozygous) and the
remainder other types of mutation.2.2. Pulmonary function
Spirometry was performed (in all patients older than 5 years)
with a bell spirometer (Biomedin-Padova, Italy). Forced
respiratory volume in 1 s (FEV1) and forced vital capacity
(FVC) are expressed as the percentage of predicted values for sex
and age [15]. These are considered the best surrogate measure in
the follow up of CF patients to assess the progression of lung
disease.
2.3. Fatty acid analysis
Whole blood, obtained from a fingertip of fasting subjects,
was collected on a special adsorbent embedded with the
antioxidant butylhydroxytoluene (Blood Collection kit, Sigma-
Aldrich, St. Louis, MO). The FA analysis of whole blood was
then carried out according to Marangoni et al. [13]. FA methyl
esters, directly prepared by transesterification, were analysed by
gas liquid chromatography (GC 1000, DANI Monza, Italy),
equipped with a PTV injector and a FID detector, using an
Omegawax 320 capillary column (Supelco, Bellefonte, PA); the
oven temperature was programmed from 120 °C to 235 °C.
2.4. Statistical analysis
A difference of around 30% in DHA levels between cases
and controls, with an expected SD of absolute values equivalent
to 0.8, according to previous data [16], would require 90 CF
subjects and 30 controls (3:1 ratio between cases and controls)
to yield a significant difference (alpha error=0.05 and power of
the test 90%).
Data analysis was performed with the statistical software
SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results were expressed as mean±SD; the significance of
differences for FA analyses between control subjects and CF
patients was assessed using the unpaired Student T-test and a
value of pb0.05 was considered significant. Possible relation-
ships between FA and different variables were investigated
using a test of linear regression, the two-tail Pearson correlation.
One-way ANOVA univariate between groups and post-hoc
Bonferroni or T3 Dunnett for multiple comparisons were
applied when CF patients were subdivided in different groups
based on FEV1%.
3. Results
Table 1 shows the characteristics of the subjects. The study
included 30 control subjects (C) with a mean age of 88 months
and weight of 30–31 kg and 90 CF patients with a mean age of
109 months and weight of 28–29 kg. The values of FEV1% and
FVC% are also reported.
The whole blood fatty acid profiles of C and CF are shown in
Table 2. Higher levels of saturated FA (SFA) and MUFA, and
lower levels of PUFA are observed in CF versus C and this
results also in a lower unsaturation index (U.I.). In particular,
total n-6 FA levels are lower in CF than in C (28.8±2.7% and
32.7±2.9% respectively) with a significant reduction of linoleic
Table 1
Characteristics of subjects in the study.
C
(n=30)
CF
(n=90)
Male/female 12/18 41/49
Age (months) 88.47±45.64 (32–188) 109.22±40.80 (50–259)
Weight (kg) 30.51±11.40 (13–60) 28.48±10.41 (14–65)
z-score for weight 0.10 (−0.50, 0.68) −0.28 (−2.46, 2.19)
FEV1% – 87.45±20.06
FVC% – 95.27±15.62
C, controls; CF, cystic fibrosis patients. Values are the mean±SD (min–max).
230 P. Risé et al. / Journal of Cystic Fibrosis 9 (2010) 228–233acid (LA, 18:2 n-6), of arachidonic acid (AA, 20:4 n-6), and of
22:4 n-6; in contrast 20:3 n-6, the direct precursor of AA, is
significantly higher in CF than in C. Total n-3 FA levels are
similar in the two groups; increased levels of 18:3 n-3 and 22:5
n-3 (DPA n-3) are found in CF versus C, whereas docosahex-
aenoic acid (DHA, 22:6 n-3), the most important product of n-3
series, is significantly lower in CF than in C. In addition, 20:3
n-9 and the 20:3 n-9/AA ratio (EFA deficiency index) are
significantly higher in CF than in C.
The FA product/precursor ratios, in the n-6 series, were also
evaluated in C and CF. The 18:3/18:2 ratio, an index of
desaturation in position 6 of the fatty acyl chain, is similar in C
and CF, whereas the 20:4/20:3 ratio, an index of desaturation in
position 5, is significantly lower in CF than in C of about 25%
(Fig. 1).
Patients and control subjects were then divided in 5 groups
on the basis of FEV1% values (Table 3). The one-way ANOVATable 2
Fatty acid profiles in whole blood of control subjects and cystic fibrosis patients.
FA
(g/100 g total FA)
C
(n=30)
CF
(n=90)
16:0 22.41±1.41 24.03±2.00 ⁎
18:0 13.13±1.16 13.21±1.25
16:1 0.85±0.45 1.06±0.51 ⁎
18:1 17.56±2.20 20.08±2.36 ⁎
20:3 n-9 0.20±0.08 0.31±0.36 ⁎
18:2 n-6 18.61±2.73 16.64±2.56 ⁎
18:3 n-6 0.27±0.23 0.28±0.13
20:3 n-6 1.61±0.32 1.73±0.37 ⁎
20:4 n-6 10.19±1.25 8.40±1.22 ⁎
22:4 n-6 1.61±0.36 1.39±0.31 ⁎
22:5 n-6 0.40±0.08 0.38±0.14
18:3 n-3 0.24±0.11 0.33±0.22 ⁎
20:5 n-3 0.21±0.18 0.23±0.10
22:5 n-3 0.78±0.18 0.84±0.17 ⁎
22:6 n-3 1.84±0.70 1.38±0.47 ⁎
SFA 40.48±1.56 41.46±1.81 ⁎
MUFA 23.57±2.11 26.62±2.65 ⁎
PUFA 35.81±2.97 31.91±2.83 ⁎
U.I. 132.56±8.15 121.69±7.41 ⁎
n-6 32.69±2.90 28.82±2.70 ⁎
n-3 3.07±0.99 2.78±0.63
20:3 n-9/AA 0.02±0.01 0.04±0.01 ⁎
DHA/AA 0.18±0.06 0.16±0.05
FA, fatty acids; C, controls; CF, cystic fibrosis patients; AA, arachidonic acid;
DHA, docosahexaenoic acid. Values are the mean±SD.
⁎ Significantly different from C at pb0.05.univariate analysis showed significant differences between
groups for oleic acid, LA, AA, DHA, SFA, MUFA, PUFA and
total n-6 (Table 3). Also the AA/20:3 n-6 ratio (Δ5 desaturation
index) and the 20:3n-9/AA ratio (EFA deficiency index) show
negative and positive trends with increasing severity of CF
( p=0.0001 and p=0.009 respectively).
Finally, the LA × DHA product is 32% lower in CF than in C
and a negative trend of this product between different groups of
FEV1% (p=0.0001) is also found (Fig. 2).
4. Discussion
This study shows that the alterations in FA profile already
described inCF are related to the severity of the pulmonary disease,
and this direct relationship has been only marginally investigated
before. We also confirm the usefulness of our analytical method in
studies on CF.
An altered FA profile in CF versus C has been described over
several years; FA analysis is usually assessed in plasma PL or in
red blood cells (RBC), in few cases in plasma total lipids or in
the cholesterol ester (CE) fraction [17–19]. Whole blood FA
analysis is a more practical and useful method to determine the
FA status in humans. In fact, as reported by Marangoni et al.
[13], this method has allowed to assess associations between
circulating FA and clinical manifestations in several conditions
and it is suitable for epidemiological and clinical studies [16]. In
addition, since the distributions of individual FA and FA classes
differ in the various lipid pools, analysis of selected lipid classes
does not provide a correct estimation of the FA status. In fact in
plasma, 69% of AA is in PL and 28% in CE, whereas more than
90% of DHA is in PL and EPA is 49% in PL and 41% in CE.
Therefore FA profiles in whole blood are more representative of
all compartments i.e. plasma (lipoproteins) and cells (RBC,
platelets), and are adequate indicators of the FA status [14]. By
analysing whole blood FA we confirmed the difference in FA
profiles, described in other specific compartments in CF
patients, i.e. higher levels of SFA and MUFA and lower levels
of PUFA. In particular, levels of LA and DHA are lower in CF
than in C, as already described in plasma PL or in RBC [20,21].
Most studies reported no variation in AA levels [17,21],
whereas we found a reduction of this FA in CF. Total n-6 FA are
decreased in CF, whereas 20:3 n-6, the direct precursor of AA,
is the only n-6 FA increased. Total n-3 FA levels are similar in
CF and C, but the significantly higher levels of ALA and DPA
are counterbalanced by lower levels of DHA. Of interest are
also the higher levels of DPA in CF. Plasma DPA n-3, not EPA
or DHA, has been reported to be associated with levels of
metalloproteinase-9 (MMP-9). In addition, high levels of DPA
n-3 are present in subjects with high serum MMP-9 levels and
this positive relationship is observed also for the DPA n-3/AA
ratio [22]. A rise of serumMMP-9 is associated to inflammatory
processes and has been reported in asthma, rheumatoid arthritis
and cancer, and increased levels of MMP-9 have been found in
sputum in CF [23]. The higher DPA n-3 levels could be
explained by the inhibition of n-3 FA conversion to DHA,
involving the desaturating enzymes. The low levels of DHA
can, at least partially, account for the chronic inflammatory state
Fig. 1. Δ6 desaturase (18:3 n-6/18:2 n-6) and Δ5 desaturase (20:4 n-6/20:3 n-6) activities, expressed as product/precursor ratios. Values are the mean±SE;
significantly different from C at *: pb0.05. C, controls; CF, cystic fibrosis patients.
231P. Risé et al. / Journal of Cystic Fibrosis 9 (2010) 228–233described in CF; in fact, DHA is the precursor of potent anti
inflammatory molecules such as resolvins [24].
In the metabolic pathway of n-6 FA, the 18:3 n-6/LA ratio,
an index of theΔ6 desaturase activity, is similar in CF and in C,
whereas the AA/20:3n-6 ratio, an index of the Δ5 desaturase
activity, is lower in CF than in C, suggesting inhibition of this
step leading to an accumulation of 20:3 n-6.
An additional observation is that 20:3 n-9 (Mead acid) and the
20:3 n-9/AA ratio, considered as an index of essential FA (EFA)
deficiency, are higher inCF than inC (indicating inadequate avail-
ability of AA derived from LA).
The relationships between FA (FA levels or FA ratios) and the
severity of disease have also been investigated. Strandvik et al.
[20] have found correlations between an altered FA profile, or
levels of selected FA, and genotype, whereas Coste et al. [19]
found correlations between FA levels and the pancreatic status.
Genotype accounts only partially for the severity of CF [25] while
FEV1 is considered the best surrogate measure for survival and
therefore the best indicator of the severity of disease. We found
significant differences between groups for FEV1% and FA (LA,Table 3
Relationships between FA (expressed as g/100 g total FA) and the severity of respir
FEV1%
C N100 80–100
n=30 n=23 n=37
OA 17.56 20.21 19.88
(13.19–23.15) (15.95–25.55) (13.69–24.
LA 18.61 16.53 16.85
(12.71–23.90) (11.58–23.21) (10.30–23.
AA 10.19 8.25 8.39
(7.27–13.24) (6.06–11.55) (6.13–10.7
DHA 1.84 1.30 1.43
(0.74–3.91) (0.73–2.81) (0.70–3.54
SFA 40.48 41.48 41.92
(37.34–45.10) (39.44–46.62) (38.35–45.
MUFA 23.57 26.61 26.10
(19.37–28.67) (21.43–31.91) (20.20–31.
PUFA 35.82 31.90 31.97
(29.48–42.18) (25.36–36.16) (25.41–38.
n-6 32.69 28.67 28.94
(25.81–39.07) (21.03–33.23) (22.03–35.
FA, fatty acids; OA, oleic acid; LA, linoleic acid; AA, arachidonic acid; DHA, docosahexae
FA. Values represent the mean (min–max) of a FA in different groups of subjects. ANOAA, DHA) or FA classes (total n-6, SFA, MUFA, PUFA). It
is important to note that the EFA deficiency index and Δ5
desaturation index are both related to the severity of disease
(positive and negative trends between groups respectively).
Two different studies described a relation of LA levels with
FEV1% [26,27] although not confirmed by a recent paper of Van
Biervliet in which no correlation between FA and FVC% or
FEV1% was found [28].
Finally, a low LA × DHA product, evaluated in plasma, was
proposed by Batal et al. as a potential diagnostic marker of CF
[29] and our data confirm that its reduction correlates with the
severity of the respiratory disease. In addition, Coste et al. have
found lower levels of this product in plasma and RBC from CF
according to the pancreatic status [19]. A limitation of the study
is the small number (n=5) of patients with a FEV 1% value
below 50; these patients are children or adolescents with an
important respiratory deficiency that greatly affects the life
expectation, and for this reason the group is poor/limited.
In conclusion, our data concerning FA profiles obtained
from whole blood analysis, in Italian CF patients, confirm inatory disease, expressed as FEV1%.
p for trend
50–79 b50
n=20 n=5
20.00 20.50 0.001
52) (17.15–23.98) (17.22–22.66)
16.53 15.43 0.013
87) (14.38–21.33) (13.16–16.72)
8.69 8.47 0.001
7) (7.19–10.55) (7.20–9.32)
1.40 1.27 0.005
) (0.60–2.38) (0.75–1.68)
41.02 41.33 0.026
97) (37.61–43.92) (39.95–43.72)
26.79 28.08 0.001
37) (23.86–31.79) (25.80–29.68)
32.19 30.59 0.001
71) (29.76–34.71) (27.82–33.25)
29.10 27.65 0.001
42) (26.48–32.28) (25.69–29.38)
noic acid; SFA, saturated FA;MUFA,monounsaturated FA; PUFA, polyunsaturated
VA univariate analysis between groups is significant at pb0.05.
Fig. 2. LA × DHA product assessed in whole blood, according to the severity of respiratory disease. A) Values are the mean±SE; significantly different from C at *:
pb0.05. B) Values are median±interquartile range at 25 and 75 percentiles. Differences between FEV1% groups were determined by ANOVA analysis significant at
pb0.05. C, controls; CF, cystic fibrosis patients; FEV1%, forced respiratory volume in 1 s.
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specific blood compartments. This micromethod-based on FA
analysis in a blood drop absorbed on special strips facilitates the
assessment of the FA status, including metabolic features, in
future studies on large numbers of patients. The correlations
found with the severity of disease deserve further confirmation
but are of interest in order to design intervention studies. Our
data support the necessity to supplement CF children with DHA
(and EFA i.e. LA), but long-term studies are needed to establish
the effect of such supplementation on the clinical course of CF.
The molecular link between the altered FA status, related to the
metabolic pathways, and the mutation in the CFTR gene also
need to be elucidated.References
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